Literature DB >> 9699630

Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site.

P Mühlhahn1, M Zweckstetter, J Georgescu, C Ciosto, C Renner, M Lanzendörfer, K Lang, D Ambrosius, M Baier, R Kurth, T A Holak.   

Abstract

The structure of a folded core of IL-16 is similar to that of intracellular protein modules called PDZ domains. IL-16 is thus the first extracellular protein found to have a PDZ-like fold. However, it does not exhibit normal peptide binding properties of PDZ domains. This is due to alterations of the structure at the 'PDZ-like binding site' of IL-16 (the GLGF cleft): the GLGF cleft of IL-16 is much smaller than those of PDZ-domains and is additionally blocked with a tryptophan side chain at its center. Our experiments indicate also that IL-16 nonspecifically aggregates in solution; but formation of a homo-tetrameric protein is not required, in contrast to previous suggestions, for its chemo-attractant activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699630     DOI: 10.1038/1376

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  11 in total

1.  The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM).

Authors:  K Ebnet; A Suzuki; Y Horikoshi; T Hirose; M K Meyer Zu Brickwedde; S Ohno; D Vestweber
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

2.  Introduction of pro-interleukin-16 inhibits T-lymphoblastic leukemia growth in mice.

Authors:  Jillian Richmond; Michael Finkel; Anna Studwell; Frederic Little; William Cruikshank
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-05       Impact factor: 4.553

3.  The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.

Authors:  R Stoll; C Renner; M Zweckstetter; M Brüggert; D Ambrosius; S Palme; R A Engh; M Golob; I Breibach; R Buettner; W Voelter; T A Holak; A K Bosserhoff
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

4.  Proteolytic cleavage of PDZD2 generates a secreted peptide containing two PDZ domains.

Authors:  Man-Lung Yeung; Tammy S M Tam; Anthony C C Tsang; Kwok-Ming Yao
Journal:  EMBO Rep       Date:  2003-03-14       Impact factor: 8.807

5.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

6.  Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Authors:  C M Leutenegger; F S Boretti; C N Mislin; J N Flynn; M Schroff; A Habel; C Junghans; S A Koenig-Merediz; B Sigrist; A Aubert; N C Pedersen; B Wittig; H Lutz
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein.

Authors:  C Kurschner; M Yuzaki
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

8.  Cryptic binding properties of a transient folding intermediate in a PDZ tandem repeat.

Authors:  Francesca Malagrinò; Giuliana Fusco; Valeria Pennacchietti; Angelo Toto; Caterina Nardella; Livia Pagano; Alfonso de Simone; Stefano Gianni
Journal:  Protein Sci       Date:  2022-09       Impact factor: 6.993

9.  Practical aspects of the 2D 15N-[1h]-NOE experiment.

Authors:  Christian Renner; Michael Schleicher; Luis Moroder; Tad A Holak
Journal:  J Biomol NMR       Date:  2002-05       Impact factor: 2.835

10.  Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16): MECHANISTIC INSIGHTS AND NEW THERAPEUTIC OPPORTUNITIES.

Authors:  Gareth Hall; Eilish Cullen; Kovilen Sawmynaden; Joanne Arnold; Simon Fox; Richard Cowan; Frederick W Muskett; David Matthews; Andrew Merritt; Catherine Kettleborough; William Cruikshank; Debra Taylor; Richard Bayliss; Mark D Carr
Journal:  J Biol Chem       Date:  2016-05-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.